More News! Smart Lens looks More Distant & a Pollen Allergy Cure?

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Sladic

  • After a long downward spiral, Genticel has become part of Genkyotex, one of the companies battling for a piece of the NASH market
  • Takeda has doubled down on Arix with a partnership following its investment in the fund’s IPO
  • Swiss biotech Addex added 3M CHF to its cash pile to extend its runway through 2018
  • Sanofi Pasteur and Medimmune are collaborating on mAbs to fight RSV-related illnesses

Sidarta

  • Asit Biotech has reported positive results from a Phase III trial for a pollen allergy cure
  • TopiVert has begun a Phase I study for its ulcerative colitis treatment
  • Merck KGaA has bagged a priority review for its checkpoint inhibitor, avelumab
  • Sanofi is partnering to launch virtual trials with Science37, an LA-based company
  • Guselkumab from Morphosys, in collaboration with Janssen, met all of its primary endpoints in Phase III for plaque psoriasis

Jiri Foltyn

  • The Chairman of Novartis, Jörg Reinhardt, took a step back from the company’s efforts to make a glucose-sensing smart lens
  • There’s a new Research Institute of Molecular Pathology at the Vienna Biocenter, following a €52M investment from Boehringer Ingelheim

Images from LadyWriter55, Jiri Foltyn, Sidarta, Sladic / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.